Dr. Debra Patt Discusses the Paradigm Shift of Treating HER2-Low Breast Cancer
The HER2-low classification offers new treatment options for advanced breast cancer patients previously labeled as HER2-negative.
Previously, patients with low expression of HER2 were categorized as HER2-negative, but adding the HER2-low classification creates new opportunities for patients with advanced breast cancer, explained Debra Patt, M.D., Ph.D., MBA, Executive Vice President, Public Policy, Payer Relations, and Strategic Initiatives at Texas Oncology.
Click here to read the full article.
Click here to read the full article.